Pooled analysis of two randomized trials comparing titanium-nitride-oxide-coated stent versus drug-eluting stent in STEMI.

[1]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[2]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[3]  R. Moreno.  El infarto agudo de miocardio es un escenario adecuado para los stents farmacoactivos , 2008 .

[4]  P. Serruys,et al.  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  I. Tamari,et al.  The Titanium-NO Stent:results of a multicenter registry. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[7]  P. Smits,et al.  Objectives Background Methods Results Conclusions , 2022 .

[8]  Antti Ylitalo,et al.  Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry. , 2011, Journal of interventional cardiology.

[9]  M. Briel,et al.  Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.

[10]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[11]  W. Nammas,et al.  Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial. , 2013, Minerva cardioangiologica.

[12]  M. Niemelä,et al.  Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  A. Dibra,et al.  Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados , 2009 .

[14]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[15]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[16]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[17]  M. Niemelä,et al.  Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. , 2013, International journal of cardiology.

[18]  P. Serruys,et al.  Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[19]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[20]  J. Tijssen,et al.  Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[21]  M. Niemelä,et al.  A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  B. Gersh,et al.  Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.

[23]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.